Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.47 |
| ▸ | PTAFR | P25105 | 7/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540698 | 0.89 | BRD4 (0.48) | BRD4PTAFROPRK1PDE4DSMN1; SMN2 | |
| SCHEMBL2537243 | 0.86 | BRD4 (0.50) | BRD4PTAFROPRK1PDE4DHPGD | |
| SCHEMBL13113724 | 0.85 | BRD4 (0.59) | BRD4PTAFROPRK1PDE4DSMN1; SMN2 | |
| SCHEMBL2541409 | 0.81 | BRD4 (0.51) | BRD4PTAFROPRK1PDE4DHPGD | |
| SCHEMBL2544545 | 0.78 | BRD4 (0.51) | BRD4PTAFROPRK1PDE4DHPGD | |
| SCHEMBL2543097 | 0.77 | BRD4 (0.46) | BRD4PTAFROPRK1PDE4DHPGD | |
| SCHEMBL2539664 | 0.77 | BRD4 (0.54) | BRD4PTAFROPRK1PDE4DHPGD | |
| SCHEMBL2536453 | 0.75 | BRD4 (0.58) | BRD4PTAFR | |
| SCHEMBL2536490 | 0.74 | BRD4 (0.47) | BRD4PTAFROPRK1PDE4DSMN1; SMN2 | |
| SCHEMBL2538074 | 0.74 | BRD4 (0.45) | BRD4PTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887008-B1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | BRD4 265/4885PTAFR 231/4885OPRK1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.